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OBJECTIVES
CONCLUSIONS
ASTROCYTES IN Aβ CLEARANCE
Mechanisms and molecules
INFLUENCE OF APOE ASTROCYTE METABOLISM AND NEURONAL 
VIABILITY
• Macropinocitosis and endocitosis clathrin-
dependent has been proposed as an
important mechanism involved in Aβ
clearance by astrocytes [3].
• Several studies suggest that scavenger
receptors and LDL receptor (LDLR) family
participate in Aβ internalization [4,3].
• In particular, it has been demonstrated that
low-density lipoprotein receptor protein 1
(LRP-1) play a major role in Aβ uptake [4].
• Alzheimer’s disease (AD) is a neurodegenerative disorder, being considered the most
prevalent cause of dementia leading to cognition decline.
• One of the major neuropathological hallmarks of Alzheimer’s disease include the
extracellular accumulation of amyloid-β (Aβ) in the brain.
• The amyloid hypothesis states that Aβ accumulation could result in alterations in
synaptic functions and other molecular and cellular events that lead to neuronal
degeneration responsible for the cognitive deficits in AD.
• Astrocytes are the major cell type in the SNC that maintain brain homeostasis. They 
have been considered important mediators of Aβ clearance helping to maintain a 
balance between its production and clearance.
• Understanding the role of astrocytes in Aβ clearance.
• Knowing which mechanisms are involved in Aβ uptake by astrocytic
cells.
• Analyzing which molecules participate in Aβ internalization and are
important in this process.
• Describing the influence of apolipoprotein E in Aβ clearance, which is
known to affect in Alzheimer’s disease.
• Considering if Aβ internalization causes alterations of astrocytic
metabolism and has consequences in neuronal viability.
• Contemplating astrocytes as a possible target in Alzheimer’s disease
therapy.
• Although it was thought that astrocytes are attracted by
amyloid plaques through chemoattractant molecules,
recent studies show that astrocytes do not migrate to Aβ
[1,2].
• Studies in vivo and in situ in adult mouse astrocyte
demonstrate that they can take up and degrade Aβ1-42
(Figure 1).
• Experiments with primary human astrocytes also show
Aβ internalization in vitro [4].
• It is suggested that size and aggregation state of Aβ is
important in Aβ clearance, where oligomers are taken up
more easily than larger fibrillar forms [4, 5].
• In experiments in vitro it has been proposed that Aβ
accumulation inside mouse astrocytes can cause disruption of
their metabolism, such as increasing glucose utilization and
stimulating reactive oxygen species production [1].
• This effects demonstrated to have consequences and end with
loss of neuronal viability.
• However, more studies are needed to understand the
mechanisms of astrocytes metabolic dysfunction in front of Aβ
effects.
• ApoE is a lipoprotein that mediates the transport and delivery of cholesterol and
other lipids.
• It has been shown that ApoE influences Aβ metabolism in the brain, although the
mechanism remains unclear [4,5]:
• It is thought that these controversies depend on (1) ApoE concentrations; (2)
ApoE isoform and lipidation state; (3) Aβ aggregation form; and (4) expression
pattern of the receptors on astrocyte surface.
Astrocytes have an important role in Aβ clearance by taking up and degrading Aβ
peptides in the brain. If Aβ uptake breaks down could lead in an increase and
aggregation of amyloid plaques. For this reason, they are being studied as a
possible target for new therapeutic strategies in Alzheimer’s disease. However,
further studies are needed in order to know exactly the mechanisms and molecules
involved, as well as the consequences in astrocytes metabolism and function.
Figure 1: Adult mouse astrocytes cultivated on Cy3-Aβ1-42
for 24h (c) and 48h (d). Red, Cy3-Aβ1-42 signal; Blue, nuclei
stained with DAPI. (i) Decrease of Aβ-immunostained with
3D6 antibody in hippocampal area of mouse expressing
human APP, after incubation without (g) or with adult
astrocytes during 24h (h) [4].
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• Some studies suggest that it facilitates Aβ clearance.
• Recent studies indicate that ApoE influences this process by competing for
the same receptors and clearance pathways within the brain.
